Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP6 | P55212 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | VCAM1 | P19320 | 2/20 | 0.45 |
| ▸ | HCAR3 | P49019 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | TPMT | P51580 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.42 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.42 |
| ▸ | MET | P08581 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31090135 | 1.00 | CASP6 (0.51) | CASP6TSHRLMNAVCAM1HCAR3 | |
| SCHEMBL30305536 | 0.86 | VCAM1 (0.45) | CASP6TSHRLMNAVCAM1ALDH1A1 | |
| SCHEMBL2368685 | 0.86 | VCAM1 (0.45) | CASP6TSHRLMNAVCAM1ALDH1A1 | |
| SCHEMBL1625709 | 0.85 | MAPT (0.44) | CASP6TSHRLMNAVCAM1ALDH1A1 | |
| SCHEMBL805262 | 0.85 | PARP1 (0.49) | TSHRLMNAVCAM1ALDH1A1MEN1 | |
| SCHEMBL13670358 | 0.82 | VCAM1 (0.41) | CASP6LMNAVCAM1HCAR3ALDH1A1 | |
| SCHEMBL70813 | 0.81 | MAPT (0.63) | LMNAVCAM1ALDH1A1MEN1KMT2A | |
| SCHEMBL27579828 | 0.81 | MAPT (0.41) | TSHRLMNAVCAM1HCAR3ALDH1A1 | |
| SCHEMBL2637045 | 0.81 | CASP6 (0.53) | CASP6TSHRLMNAHCAR3ALDH1A1 | |
| SCHEMBL28350595 | 0.80 | MAPT (0.40) | CASP6TSHRLMNAVCAM1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 170 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114149409-B | (hetero) aryl amide compound with protein kinase inhibition activity | 中国药科大学 | 2024-03-22 | — | — | CN | claimed |
| CN-115109048-A | (hetero) aryl amide compound | 中国药科大学 | 2022-09-27 | — | — | CN | claimed |
| CN-114149409-A | (hetero) aryl amide compound with protein kinase inhibitory activity | 中国药科大学 | 2022-03-08 | — | — | CN | claimed |
| CN-113429426-A | Amide compound and preparation method and application thereof | 嘉兴金派特生物科技有限公司 | 2021-09-24 | — | — | CN | claimed |
| CN-112441970-A | 2, 5-disubstituted-3-aminopyridine compound and preparation method and application thereof | 天津医科大学 | 2021-03-05 | — | — | CN | claimed |
| EP-4007758-B1 | BIS-[N-((5-CARBAMOYL)-1H-BENZO[D]IMIDAZOL-2-YL)-PYRAZOL-5-CARBOXAMIDE] DERIVATIVES AND RELATED COMPOUNDS AS STING (STIMULATOR OF INTERFERON GENES) AGONISTS FOR THE TREATMENT OF CANCER | MERSANA THERAPEUTICS INC (US) | 2026-05-13 | — | — | EP | disclosed |
| EP-4651907-A1 | DRUG CONJUGATES AND METHODS OF PREPARING AND USING THE SAME | Adcentrx Therapeutics Inc. (US) | 2025-11-26 | — | — | EP | disclosed |
| EP-4605392-A1 | METHODS FOR TREATING CANCER | Antares Therapeutics, Inc. (US) | 2025-08-27 | — | — | EP | disclosed |
| EP-4594318-A1 | AKT1 MODULATORS | Alterome Therapeutics, Inc. (US) | 2025-08-06 | — | — | EP | disclosed |
| WO-2025120168-A1 | SULFONAMIDE DERIVATIVES AND USE THEREOF IN THE TREATMENT OF CRYPTOSPORIDIUM INFECTIONS | INSTITUT NATIONAL DE RECHERCHE POUR L'AGRICULTURE, L'ALIMENTATION ET L'ENVIRONNEMENT (INRAE) (FR) | 2025-06-12 | — | — | WO | disclosed |
| US-20250108048-A1 | STING AGONIST COMPOUNDS AND CONJUGATES | SUTRO BIOPHARMA, INC. | 2025-04-03 | — | — | US | disclosed |
| US-20250092040-A1 | AKT1 MODULATORS | ALTEROME THERAPEUTICS, INC. | 2025-03-20 | — | — | US | disclosed |
| WO-1999052896-A1 | HETEROCYCLIC GLYCYL BETA-ALANINE DERIVATIVES AS VITRONECTIN ANTAGONISTS | G.D. SEARLE & CO. (US) | 1999-10-21 | — | — | WO | disclosed |
| US-5886008-A | 5-arylindole derivatives | PFIZER INC. (US) | 1999-03-23 | — | — | US | disclosed |
| EP-0666858-A1 | 5-ARYLINDOLE DERIVATIVES AND THEIR USE AS SEROTONIN (5-HT 1?) AGONISTS | PFIZER INC. (US) | 1995-08-16 | — | — | EP | disclosed |
| WO-1994010171-A1 | 5-ARYLINDOLE DERIVATIVES AND THEIR USE AS SEROTONIN (5-HT1) AGONISTS | PFIZER INC. (US) | 1994-05-11 | — | — | WO | disclosed |
| US-4393212-A | ADRENERGIC BLOCKING AGENTS | MERCK & CO., INC. (US) | 1983-07-12 | — | — | US | disclosed |
| US-4294969-A | COUPLING N-BROMOSUCCINIMIDE AND A 2-BROMOPYRIDINE | MERCK & CO., INC. (US) | 1981-10-13 | — | — | US | disclosed |
| US-4279913-A | ANTIARRYTHMIA, HYPOTENSIVE | MERCK & CO., INC. (US) | 1981-07-21 | — | — | US | disclosed |
| EP-0003278-A1 | Polysubstituted-2-(3-loweralkylamino-2-R0-propoxy)pyridines, process for preparing the same, and pharmaceutical compositions containing the same | MERCK & CO. INC. (US) | 1979-08-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250108048-A1 | STING AGONIST COMPOUNDS AND CONJUGATES | STING1, CGAS, MAVS | CASP6 1906/4885TSHR 2275/4885LMNA 2064/4885 |
| US-20250092040-A1 | AKT1 MODULATORS | AKT1S1, AKT1, AKT2 | CASP6 2308/4885TSHR 3990/4885LMNA 3201/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.